Dr. Hyer has more than 15 years of experience in biotechnology with vaccines, biologics, and biosimilars. In November 2021, Dr. Hyer stepped down as Senior Vice President for Global Medical Affairs at Moderna where he worked on the FDA approval and launch of its mRNA COVID-19 vaccine. Prior to Moderna, he headed Clinical Development and Medical Affairs at Dynavax, where he helped achieve approval of HEPLISAV-B, a new two-dose hepatitis B vaccine with a novel adjuvant. He left Moderna to launch Merlin Biotech and brings with him a wealth of development success.
OTHER BOARD OF DIRECTORS MEMBERS
